Applications of Mass Spectrometry for Therapeutic Drug Monitoring (TDM)
Paul J. Jannetto (1), William Clarke (2) (1) Department of Laboratory Medicine and Pathology, Mayo Clinic; (2) Department of Pathology, Johns Hopkins Hospital
Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704
Paul Jannetto (Presenter) Mayo Clinic
Presenter Bio: Paul J. Jannetto, Ph.D., DABCC, FAACC, M.T.(ASCP), is a Consultant at the Mayo Clinic (Rochester, MN) where he serves as the Co-Director for the Clinical Mass Spectrometry Laboratory, Clinical and Forensic Toxicology Laboratory and the Metals Laboratory.His clinical and scientific interests are centered on pain management testing, novel therapeutic agents, and elemental toxicity.
Relevant Financial Disclosures
(within past 24 months)
No relevant financial relationship(s) to disclose.
Abstract
As more laboratories continue to bring up mass spectrometry-based tests, this presentation will summarize some of the technical considerations, clinical issues, and financial requirements that are important to determine if therapeutic drug targets should be analyzed using this technology. The advantages and disadvantages of using liquid chromatography tandem mass spectrometry (LC-MS/MS) versus traditional immunoassays for drugs will be discussed. In addition, this session will also discuss future opportunities and targets for TDM testing using mass spectrometry.
= Discovery stage. (17.55%, 2019 US)
= Translation stage. (42.72%, 2019 US)
= Clinically available. (39.74%, 2019 US)
